Hemorrhagic transformation after acute ischemic stroke thrombolysis treatment: navigating the landscape of hemostasis genetic risk factors

Stroke is a common vascular disease with high morbidity and mortality, representing a substantial socio-economic burden worldwide [1]. Eighty percent of all strokes are of ischemic origin, 12% to 15% are hemorrhagic, and the remainder consists of subarachnoidal bleeding. In the case of acute ischemic stroke (AIS), the patient's only prospect of recovery depends on the successful opening of the occluded vessel. Currently, there are 2 evidence-based, FDA-approved therapeutic options addressing this need.